Search clinical trials for: Nepafenac Ophthalmic

Total 1673 results

Alcon Research

Completed

Confirmatory Study Nepafenac 0.3%

Cataract

United States
Alcon Research

Completed

Nepafenac 0.3% Two Study

Cataract

United States
Alcon Research

Completed

Nepafenac Compared to Placebo for Ocular Pain and Inflammation

Cataract

China
Toyos Clinic
Bausch & Lomb Incorporated

Completed

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Inflammation | Pseudophakia
Melissa Toyos
Bausch & Lomb Incorporated

Completed

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery (QD)

Inflammation | Cataract | Retinal Edema

United States
Alcon Research

Terminated

Macular Edema Incidence/Severity Reduction With Nevanac

Diabetic Retinopathy

United States
Alcon Research

Completed

Nevanac 3-Month Safety Study With QID Dosing

Cataract

United States
Alcon Research

Completed

Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

Cataract

United States
Oslo University Hospital

Recruiting

Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN) (pre-CIN)

Cataract Surgery

Norway
Oslo University Hospital

Recruiting

DSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC) (DMEC)

Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) | Descemet Membrane Endothelial Keratoplasty (DMEK)

Norway
Assiut University

Unknown

Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery

Cataract | Miosis
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Hanlim Pharm. Co., Ltd.

Completed

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

Healthy Subject
Alcon Research

Completed

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients

Macular Edema
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
University Hospital of Patras

Completed

Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections

Pain

Greece
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Inflammation and Pain Following Ocular Surgery

United States
Alcon Research

Completed

Nepafenac Once Daily for Macular Edema - Study 1

Cataract | Non-Proliferative Diabetic Retinopathy
Jaeb Center for Health Research
National Eye Institute (NEI)

Completed

NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)

Diabetic Macular Edema

United States
Alcon Research

Completed

Nepafenac Once Daily for Macular Edema - Study 2

Cataract | Non-Proliferative Diabetic Retinopathy
University of Trieste

Completed

PGE2 Levels in Patient Treated With NSAIDs

Ocular Inflammation

Italy
Mitotech, SA
ORA, Inc.

Completed

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Keratoconjunctivitis Sicca

United States
Alcon Research

Completed

Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo

Cataracts

France
Sheba Medical Center

Unknown

Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy

Glaucoma, Angle-Closure | Glaucoma, Closed-Angle | Glaucoma, Narrow-Angle

Israel
Actavis Inc.

Completed

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

Cataract

United States
University Hospital of Patras

Completed

Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections

Pain

Greece
Shiraz University of Medical Sciences

Completed

Probiotic in Dry Eye Syndromes

Dry Eye Syndrome

Iran, Islamic Republic of
L.V. Prasad Eye Institute
Allergan

Recruiting

CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops

Congenital Hereditary Endothelial Dystrophy of Cornea

India
Alcon Research

Completed

Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery

Epiretinal Membrane

United States
Intuor Technologies, Inc.

Completed

Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Cystoid Macular Edema
Universiti Sains Malaysia

Completed

Topical Nepafenac as Supplement for Diabetic Macular Edema

Diabetic Macular Edema

Malaysia
Dr T V Patel Eye Institute

Completed

Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes

Intraocular Pressure

India
Università degli Studi di Brescia

Completed

NSAIDs and PGE2 Levels in Vitrectomy Patients

Vitreous Inflammation
Mati Therapeutics Inc.

Completed

Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract

Pain | Inflammation

United States
University of North Carolina, Chapel Hill
Research to Prevent Blindness

Completed

Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery

Cystoid Macular Edema

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Ocular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract Surgery

United States
Center For Excellence In Eye Care
Allergan

Completed

Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK

Myopia | Hyperopia
Bp Consulting, Inc

Completed

Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)

Intraocular Pressure

United States
Chengdu Kanghong Biotech Co., Ltd.

Completed

Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion (BRAVE)

Macular Edema | Branch Retinal Vein Occlusion

China
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Laboratorios Sophia S.A de C.V.

Withdrawn

Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis (PRO-118)

Conjunctivitis, Allergic | Seasonal Allergic Conjunctivitis | Ocular Itching | Ocular Allergy | Perennial Allergic Conjunctivitis

Mexico
University of the Incarnate Word

Unknown

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

Glaucoma, Open-Angle

United States
Aerie Pharmaceuticals

Completed

Ocular Hypotensive Efficacy of AR-102

Glaucoma

United States
Alcon Research

Completed

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States

3

Subscribe